Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study

Journal of Endocrinological Investigation

Volumn 28, Issue 9, 2005, Pages 806-809

  Erdogan, M F ^a   Gursoy A ^a   Ozgen G ^c   Cakir M ^e   Bayram, F ^f   Ersoy, R ^b   Algun E ^g   Cetinarslan B ^h   Comlekci A ^d   Kadioglu, P ⁱ   Bald, M K ^e   Yetkin, I ^b   Kabalak, T ^c   Erdogan, G ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

^e AKDENIZ UNIVERSITY   (Turkey)

^f ERCIYES UNIVERSITY   (Turkey)

^g YUZUNCU YIL UNIVERSITY   (Turkey)

^h KOCAELI UNIVERSITY   (Turkey)

ⁱ ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Multiple endocrine neoplasia type 2; Ret protooncogene; Sporadic medullary thyroid carcinoma

Indexed keywords

CALCITONIN;

ADULT; ARTICLE; CLINICAL TRIAL; CODON; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ENDOCRINE NEOPLASIA; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA; TURKEY (REPUBLIC);

EID: 31544460391     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03347570     Document Type: Article

References (25)

1. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: recent advances and management update. Thyroid 1995, 5: 407-24.
2. Raue F, Frank-Raue K, Grauer A. Multiple endocrine neoplasia type 2, clinical features and screening. Endocrinol Metab Clin North Am 1994, 23: 137-56.
3. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363: 458-60.
4. Donis-Keller H, Dou S, Chi D, et al. Mutations in RET protooncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2: 851-6.
5. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999, 17: 380-93.
6. Schuffenecker I, Billaud M, Calender A, et al. RET proto-oncogene mutations in French MEN 2A and FMTC patients. Hum Mol Genet 1994, 3: 1939-43.
7. Frank-Raue K, Hoppner W, Frilling A, et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: Relation between genotype end phenotype. J Clin Endocrinol Metab 1996, 81: 1780-3.
8. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET protooncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994, 6: 70-4.
9. Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995, 238: 343-6.
10. Eng C, Clayton D, Schuffenecker I, et al. The relation between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplaia type 2: international RET Mutation Consortium analysis. JAMA 1996, 276: 1575-9.
11. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86: 5658-71.
12. Pichel JG, Shen L, Sheng HZ. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1993, 363: 458-60.
13. Sanchez MP, Silos-Santiago I, Frisen J, He B, Lira SA, Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 1996, 382: 70-3.
14. Eng C. RET proto-oncogene in the development of human cancer. J Clin Onc 1999, 17: 380-93.
15. Klein RD, Sherman D, Ho WH, et al. A gpi-linked protein that interacts with ret to form a candidate neurturin receptor. Nature 1998, 392: 210-3.
16. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367: 375-6.
17. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004, 61: 299-310.
18. Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Intern Med 2003, 253: 616-26.
19. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C. Somatic and MEN 2A de novo mutations identified in the RET protooncogene by screening of sporadic MTC:s. Hum Mol Genet 1994, 3: 1259-62.
20. Wohllk N, Cote GJ, Bugalho MM, et al. Relevance of RET protooncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996, 81: 3740-5.
21. Conte-Devolx B, Schuffenecker I, Niccoli P, et al. Multiple endocrine neoplasia type 2: management of patients and subjects at risk. French Study Group on Calcitonin-Secreting Tumors (GETC). Horm Res 1997, 47: 221-6.
22. Lallier M, St-Vil D, Giroux M, et al. Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome. J Pediatr Surg 1998, 33: 846-8.
23. Lips CJ. Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. J Intern Med 1998, 243: 589-94.
24. Wells SA Jr, Skinner MA. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998, 106: 29-34.
25. Vieira AE, Mello MP, Elias LL, et al. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A. Horm Metab Res 2002, 34: 202-6.